Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MD - Pediatrix Medical Group, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$26.60
DETAILS
HIGH:
$28.00
LOW:
$24.00
MEDIAN:
$28.00
CONSENSUS:
$26.60
DOWNSIDE:
2.85%
Stock News
HB Wealth Expands Into Texas With Experienced Three-Advisor Team
ATLANTA--(BUSINESS WIRE)--HB Wealth, one of the nation's largest independent, fee-only registered investment advisers, today announced that Steven D. Podnos, MD, MBA, CFP®, Rachel Podnos O'Leary, JD, CFP®, and Lauren Podnos-Garner, CFP®, have joined the firm. Together, the three advisors establish the firm's presence in Austin, Texas, with Rachel and Lauren based in Austin and Steven dividing his time between Austin and Cocoa Beach, Florida. The trio previously operated Wealth Care LLC, an inde.
Can Pediatrix Sustain Growth Despite Lower Patient Volumes?
MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.
Engineers Gate Manager LP Lowers Stock Position in Pediatrix Medical Group, Inc. $MD
Engineers Gate Manager LP trimmed its holdings in Pediatrix Medical Group, Inc. (NYSE: MD) by 60.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,871 shares of the company's stock after selling 77,533 shares during the quarter. Engineers Gate Manager LP
Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sinopharm Group (OTCMKTS:SHTDY) and Pediatrix Medical Group (NYSE:MD) Financial Survey
Sinopharm Group (OTCMKTS:SHTDY - Get Free Report) and Pediatrix Medical Group (NYSE: MD - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Analyst Recommendations This is a breakdown of
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?
Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen's TEZSPIREÂ (te
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio
MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pediatrix Medical Tops Q2 Earnings on Better Cash Collections
MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.
Pediatrix Medical Group Q2 Earnings Call Highlights
Pediatrix Medical Group NYSE: MD reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management collections, payer mix and patient acuity offset lower patient-service volumes.
Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript
Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript
Pediatrix Medical Group (MD) Beats Q2 Earnings and Revenue Estimates
Pediatrix Medical Group (MD) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.53 per share a year ago.
Pediatrix Medical Group Reports Second Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports Second Quarter Results.
Allspring Global Investments Holdings LLC Acquires 335,733 Shares of Pediatrix Medical Group, Inc. $MD
Allspring Global Investments Holdings LLC increased its holdings in Pediatrix Medical Group, Inc. (NYSE: MD) by 52.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 975,133 shares of the company's stock after acquiring an additional 335,733 shares during the period.
Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Rating of “Hold” from Analysts
Shares of Pediatrix Medical Group, Inc. (NYSE: MD - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year
Pediatrix Medical Group (MD) Soars 7.3%: Is Further Upside Left in the Stock?
Pediatrix Medical Group (MD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Price Targets
Jefferies Downgrades Pediatrix Medical Group (MD) to Hold
$28.00
(was $26.56)
Brian Tanquilut
·
Jefferies
Pediatrix Medical price target raised to $28 from $25 at UBS
$28.00
(was $25.99)
UBS
Pediatrix Medical price target raised to $25 from $19 at Deutsche Bank
$25.00
(was $26.07)
Pito Chickering
·
Deutsche Bank
Pediatrix Medical price target raised to $28 from $23 at Truist
$28.00
(was $26.14)
Truist Financial
Pediatrix Medical price target raised to $25 from $22 at UBS
$25.00
(was $23.42)
UBS
Pediatrix Medical price target raised to $24 from $21 at Mizuho
$24.00
(was $22.93)
Mizuho Securities
Pediatrix Medical price target raised to $27 from $24 at Jefferies
$27.00
(was $23.21)
Jack Slevin
·
Jefferies
Pediatrix Medical price target lowered to $22 from $23 at UBS
$22.00
(was $19.20)
UBS
Pediatrix Medical price target lowered to $19 from $21 at Deutsche Bank
$19.00
(was $18.80)
Deutsche Bank
Pediatrix Medical price target lowered to $21 from $24 at Truist
$21.00
(was $18.41)
Truist Financial
Pediatrix Medical price target raised to $24 from $17 at Truist
$24.00
(was $22.30)
David MacDonald
·
Truist Financial
Pediatrix Medical price target raised to $23 from $16.50 at UBS
$23.00
(was $21.46)
UBS
Pediatrix Medical price target raised to $17 from $16 at Truist
$17.00
(was $16.04)
David MacDonald
·
Truist Financial
Pediatrix Medical price target raised to $13 from $10 at Truist
$13.00
(was $12.13)
David MacDonald
·
Truist Financial
Jefferies Upgrades Pediatrix Medical Group (MD) to Buy
$14.00
(was $11.26)
Jack Slevin
·
Jefferies
Pediatrix Medical Group (MD) PT Raised to $10 at Truist Securities
$10.00
(was $10.16)
David MacDonald
·
Truist Financial
Deutsche Bank Upgrades Pediatrix Medical Group (MD) to Hold
$8.00
(was $6.89)
Pito Chickering
·
Deutsche Bank
Credit Suisse Maintains Outperform on Pediatrix Medical Group, Lowers Price Target to $27
$27.00
(was $16.28)
Credit Suisse
Credit Suisse Maintains Outperform on Pediatrix Medical Group, Lowers Price Target to $28
$28.00
(was $21.27)
Credit Suisse
Credit Suisse Maintains Outperform on Mednax, Lowers Price Target to $30
$30.00
(was $19.02)
Credit Suisse